39 related articles for article (PubMed ID: 11125370)
1. Radiomics and Clinicopathological Characteristics for Predicting Lymph Node Metastasis in Testicular Cancer.
Lisson CS; Manoj S; Wolf D; Lisson CG; Schmidt SA; Beer M; Thaiss W; Bolenz C; Zengerling F; Goetz M
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067334
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours.
Conduit C; Hong W; Martin F; Thomas B; Lawrentschuk N; Goad J; Grimison P; Ahmadi N; Tran B; Lewin J
Front Oncol; 2022; 12():931509. PubMed ID: 36059636
[TBL] [Abstract][Full Text] [Related]
3. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
[TBL] [Abstract][Full Text] [Related]
4. Validation of a prediction model for avoiding post-chemotherapy retroperitoneal lymphadenectomy in patients with metastatic nonseminomatous germ cell cancer.
Punjani N; Power N; Vanhie JJ; Winquist E
Can Urol Assoc J; 2016 Aug; 10(7-8):260-263. PubMed ID: 27878048
[TBL] [Abstract][Full Text] [Related]
5. Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?
Riggs SB; Burgess EF; Gaston KE; Merwarth CA; Raghavan D
Oncologist; 2014 May; 19(5):498-506. PubMed ID: 24718515
[TBL] [Abstract][Full Text] [Related]
6. Predictors of viable germ cell tumor in postchemotherapeutic residual retroperitoneal masses.
Al Othman K; Al Hathal N; Mokhtar A
Urol Ann; 2014 Jan; 6(1):27-30. PubMed ID: 24669118
[TBL] [Abstract][Full Text] [Related]
7. Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.
Heidenreich A; Pfister D
Ther Adv Urol; 2012 Aug; 4(4):187-205. PubMed ID: 22852029
[TBL] [Abstract][Full Text] [Related]
8. Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.
Daneshmand S; Djaladat H; Nichols C
Ther Adv Urol; 2011 Aug; 3(4):163-71. PubMed ID: 21969846
[TBL] [Abstract][Full Text] [Related]
9. Assessing the performance of prediction models: a framework for traditional and novel measures.
Steyerberg EW; Vickers AJ; Cook NR; Gerds T; Gonen M; Obuchowski N; Pencina MJ; Kattan MW
Epidemiology; 2010 Jan; 21(1):128-38. PubMed ID: 20010215
[TBL] [Abstract][Full Text] [Related]
10. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients.
Vergouwe Y; Steyerberg EW; de Wit R; Roberts JT; Keizer HJ; Collette L; Stenning SP; Habbema JD
Br J Cancer; 2003 Mar; 88(6):843-7. PubMed ID: 12644820
[TBL] [Abstract][Full Text] [Related]
11. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.
Steyerberg EW; Gerl A; Fossá SD; Sleijfer DT; de Wit R; Kirkels WJ; Schmeller N; Clemm C; Habbema JD; Keizer HJ
J Clin Oncol; 1998 Jan; 16(1):269-74. PubMed ID: 9440752
[TBL] [Abstract][Full Text] [Related]
12. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group.
Steyerberg EW; Donohue JP; Gerl A; Toner GC; Schraffordt Koops H; Fosså SD; Keizer HJ
J Urol; 1997 Aug; 158(2):474-8. PubMed ID: 9224327
[TBL] [Abstract][Full Text] [Related]
13. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies.
Sheinfeld J
Semin Urol Oncol; 2002 Nov; 20(4):262-71. PubMed ID: 12489059
[TBL] [Abstract][Full Text] [Related]
14. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer.
Vergouwe Y; Steyerberg EW; Foster RS; Habbema JD; Donohue JP
J Urol; 2001 Jan; 165(1):84-8; discussion 88. PubMed ID: 11125370
[TBL] [Abstract][Full Text] [Related]
15. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
Steyerberg EW; Keizer HJ; Messemer JE; Toner GC; Schraffordt Koops H; Fosså SD; Gerl A; Sleijfer DT; Donohue JP; Habbema JD
Cancer; 1997 Jan; 79(2):345-55. PubMed ID: 9010108
[TBL] [Abstract][Full Text] [Related]
16. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
